Background:
Type 2 diabetes is caused by unhealthy lifestyles, such as consuming foods rich in simple sugars and lack of exercise. One of the treatment therapies for this disease is α-glucosidase inhibitors. Some strains of the lactic acid bacteria (LAB) group typically exhibit α-glucosidase inhibitory activity, antimicrobial activity, acids and bile salt tolerance, and probiotic status.
Objective:
This study aims to isolate LAB from naniura, characterize and test its activity as an α-glucosidase inhibitor, as well as identify those with the highest activity.
Methods:
The method used to molecularly identify potentially good LAB was through the amplification of the 16S rRNA gene.
Results:
This study obtained a total of 9 strains using BAMA codes 1, 2, 3, 4, 5, 6, 7, 8, and 9. The cocci cell activity, gram-positive, and antibacterial activity of BAMA 4 against E.coli was 7.54 mm, while against S. aureus was 8.05 mm. The percentage of viability in acid and bile salt is 28.7% and 68.6%, respectively. Additionally, the proportion of α-glucosidase inhibition is 65%.
Discussion:
The BAMA 4 strain is a species of Pediococcus acidilactici. Pediococcus is a genus of gram-positive lactic acid bacteria in the Lactobacillacea family.
Conclusion:
BAMA 4 strain produced antibacterial optimally and its cells survived the growth in acid and bile conditions. The percentage of probiotics was relevantly high in this activity. This study will be helpful for other in-vivo research.